RPTR-147:1 / Repertoire - LARVOL DELTA

[VIRTUAL] PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients (SITC 2020) - P1 | "Dose-escalation is proceeding. Ongoing biomarker analysis will inform future clinical strategies in matching patients to an optimized PRIME IL-15 T cell product."

Biomarker • Clinical • IO Biomarker • Late-breaking abstract • P1 data • Oncology • Solid Tumor • BIRC5 • CD8 • IL15 • PRAME

KEYNOTE KN-948: RPTR-147 in Patients With Selected Solid Tumors and Lymphomas (clinicaltrials.gov) - P1/2 | N=23 | Terminated | Sponsor: Repertoire Immune Medicines | Trial completion date: Jul 2026 ➔ Oct 2022 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jul 2026 ➔ Sep 2022; Development program terminated

Combination therapy • Trial completion date • Trial primary completion date • Trial termination • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

KEYNOTE KN-948: RPTR-147 in Patients With Selected Solid Tumors and Lymphomas (clinicaltrials.gov) - P1/2 | N=23 | Active, not recruiting | Sponsor: Repertoire Immune Medicines | Recruiting ➔ Active, not recruiting | N=240 ➔ 23

Combination therapy • Enrollment change • Enrollment closed • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

KEYNOTE KN-948: RPTR-147 in Patients With Selected Solid Tumors and Lymphomas (clinicaltrials.gov) - P1/2 | N=240 | Recruiting | Sponsor: Repertoire Immune Medicines | Trial completion date: Feb 2023 ➔ Jul 2026 | Trial primary completion date: Feb 2023 ➔ Jul 2026

Combination therapy • Trial completion date • Trial primary completion date • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

[VIRTUAL] PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients (SITC 2020) - P1 | "Dose-escalation is proceeding. Ongoing biomarker analysis will inform future clinical strategies in matching patients to an optimized PRIME IL-15 T cell product."

Biomarker • Clinical • IO Biomarker • Late-breaking abstract • P1 data • Oncology • Solid Tumor • BIRC5 • CD8 • IL15 • PRAME

[VIRTUAL] Tracking and decoding the antigen specificity of peripherally derived T cells that infiltrate into solid tumors in patients treated with an autologous T cell therapy, PRIME IL-15 (RPTR-147) (AACR 2021) - "Antigen specific T cell reactivities and clonotypes were identified in the peripheral repertoire. We confirmed that T cells were successfully expanded against TAAs and that these T cells do infiltrate the tumors as evidenced by bulk TCR sequencing of post-treatment tumor biopsies."

Clinical • IO biomarker • Late-breaking abstract • Oncology • Solid Tumor • BIRC5 • CD4 • CD8 • IFNG • IL15 • PRAME • WT1

Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck Cancers (Businesswire) - "Repertoire Immune Medicines...announced a research collaboration with Dana-Farber Cancer Institute to advance discovery and clinical development in human papillomavirus-positive (HPV+) oropharyngeal (head and neck) cancers...The results of this research collaboration will inform Repertoire’s selection of tumor antigens for T cell therapy investigation that have the potential to be integrated into clinical trials...Ravindra Uppaluri...Dana-Farber is currently a site for an ongoing Phase I clinical trial of Repertoire’s PRIME™ IL-15..."

Licensing / partnership • Head and Neck Cancer • Oncology • Oropharyngeal Cancer

Repertoire Immune Medicines to Present Data from Autologous T Cell Therapy -- PRIME IL-15 (RPTR-147) -- in Advanced or Metastatic Solid Tumor Cancers (Businesswire) - "Repertoire Immune Medicines...announced the presentation of translational data obtained from applying its proprietary antigen-specific TCR-MHC DECODE™ platform in its Phase 1 trial evaluating PRIME IL-15 (RPTR-147) in patients with advanced or metastatic solid tumor cancers. The data will be presented at the American Association of Cancer Research (AACR) Virtual Meeting Week 1, taking place April 10-15, 2021."

P1 data • Oncology • Solid Tumor

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas (clinicaltrials.gov) - P1/2; N=240; Recruiting; Sponsor: Repertoire Immune Medicines; Active, not recruiting ➔ Recruiting; Phase classification: P1 ➔ P1/2; N=20 ➔ 240; Trial completion date: Sep 2021 ➔ Feb 2023; Trial primary completion date: Sep 2021 ➔ Feb 2023

Clinical • Combination therapy • Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Repertoire Immune Medicines to Provide Progress Updates on Clinical Programs and Discovery Platform at J.P. Morgan Healthcare Conference (Businesswire) - "Repertoire Immune Medicines...today announced that John Cox, Chief Executive Officer, will participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021...Repertoire has initiated enrollment of the next cohort of patients in a Phase 1/2 study of PRIME IL-15 in patients with advanced metastatic solid tumors...Additional clinical data from the PRIME IL-15 study are anticipated in the second half of 2021."

P1/2 data • Trial status • Oncology • Solid Tumor

Repertoire Immune Medicines Presents First Clinical Data on PRIME IL-15 Cell Therapy in Advanced Metastatic Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting (Businesswire) - “Repertoire Immune Medicines…revealed preliminary clinical and biomarker data of a Phase 1/2 clinical study for its PRIME IL-15 cell therapy (RPTR-147) in patients with advanced metastatic solid tumors. Preliminary results from the ongoing study will be available on the SITC Virtual Poster Hall, November 11 - 14, from 9 a.m. to 5 p.m. EST. The poster is titled “PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients” (#801)....'These preliminary PRIME IL-15 clinical results, showing that disease in 10 of 17 patients with aggressive cancers has stabilized, is encouraging,' said Harriet Kluger, M.D...”

Media quote • P1/2 data • Oncology • Solid Tumor